Overview: aliskiren is a second-generation renin inhibitor, which acts on the first rate limiting step of renin angiotensin aldosterone system (RAS). At present, all research data show that alikelen antihypertensive treatment has good safety and effectiveness, less side effects, long half-life and convenient to take once a day. It has entered phase III clinical practice and is expected to become the first oral renin inhibitor for the treatment of hypertension, other cardiovascular diseases and nephropathy.
Properties
Summary
Alikelen is a second-generation renin inhibitor, which acts on the first rate limiting step of renin angiotensin aldosterone system (RAS). At present, all research data show that alikelen antihypertensive treatment has good safety and effectiveness, less side effects, long half-life and convenient to take once a day. It has entered phase III clinical practice and is expected to become the first oral renin inhibitor for the treatment of hypertension, other cardiovascular diseases and nephropathy.
CRO
